DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-46 of U.S. Patent No. 11,918,423. Although the claims at issue are not identical, they are not patentably distinct from each other because claim 1 of the present application and claim 18 of the patent are both directed to a system for delivering an elongated medical device along a path to a target location including a catheter procedure system coupled to an imaging system, a bedside system, a controller coupled to the bedside system as well as the steps of generating a mask, tracking the position of a distal portion, determine a remaining path length, the particulars of the remaining path length as well as updating the remaining path length, determining if the distal portion of the elongated medical device is off path, a corrective action (i.e., adjust the position – as stated in the patent) and drive the elongated medical device at a velocity determined by the remaining path length (advance and adjust the velocity – as stated in the patent). Claim 18 of the patent includes additional features including a child vessel and child vessel mask as well as displaying the mask and the child vessel mask and the velocity is proportional to the remaining path length. These are features which are disclosed in claims 2-4 of the present application. Claim 1 of the present application does not actively set forth the imaging system as stated in claim 18 of the patent; however, claim 1 does disclose the catheter procedure system being coupled to an imaging system.
Claim 5 includes all of the particulars of claim 18 of the patent with the exception of a positively recited imaging system, a workstation, a user interface and a display. In view of the recitation of all of the limitations of claim 5 being in claim 18 of the patent, claim 5 of the present application is anticipated by claim 18 of the patent. Claims 6-22 are anticipated by 19-35 of the patent.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 3, 7 and 19-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 3 recites the limitation "the child vessel mask" in line 2. There is insufficient antecedent basis for this limitation in the claim.
Claim 7 recites the limitation "the workstation" in line 1. There is insufficient antecedent basis for this limitation in the claim.
Claim 19 recites the limitation "the workstation" in line 1. There is insufficient antecedent basis for this limitation in the claim.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1 and 4 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cohen et al (2015/0282890) in view of Soper et al (2013/0158346) and further in view of Atarot et al (2017/0202624).
Regarding claims 1 and 4, Cohen et al disclose a system for delivering an elongated medical device along a path to a target location, the system comprising:
a catheter procedure system configured to be coupled to an imaging system ([0743]), the catheter procedure system comprising:
a bedside system comprising a drive assembly configured to drive an elongated medical device (medical tool, tool, device, probe – [0742]); and
a controller coupled to the bedside system (at least one processor – [0246]), wherein the controller is programmed to
generate a mask, which is applied to an image for clarifying the defined path (applying a mask derived from a road map – [1039]);
track the position of a distal portion of the elongated medical device based on a set of real-time images acquired by an imaging system (the native image stream may be image tracked with respect to the distal tip of the guiding catheter – [0759]; a current image stream of the tool inside the blood vessel is generated – [0921]);
determining a remaining path length based at least on the position of the distal portion of the elongated medical device, the remaining path length being a distance between the distal portion of the elongated medical device and the target location, wherein the remaining path length decreases as the distal portion of the elongated medical device approaches the target location (track the location of device markers relative to a lesion, thereby facilitating the correct deployment of the device – [0980]);
update the remaining path length during movement of the elongated medical device (image tracking with respect to a radiopaque segment or marker of the tool – [0879]; track the location of device markers relative to a lesion – [0980]; the remaining length is updated by virtue of the updated image).
Cohen et al fail to explicitly disclose determine if the distal portion of the elongated medical device is off path and drive the elongated medical device with a corrective action using the drive assembly if the result of the determination indicates that the distal portion of the elongated medical device is off path.
However, Soper et al teach in the same medical field of endeavor, determine in a distal portion of an elongated medical device is off path and drive the elongated medical device with a corrective action using a drive assembly if the result of the determination indicates the distal portion of the elongated medical device is off path (if the distance from the intended destination should continue to increase beyond an accepted limit, the clinician may be directed to back up to a previous one or more bifurcation and take a different path – [0101]).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to modify the tracking of the path of the instrument of Cohen et al with determining whether the medical device is off path and drive a corrective action of Soper et al as it would provide correct navigation of the instrument to a target location.
Cohen et al as modified by Soper et al fail to explicitly disclose drive the elongated medical device at a velocity determined based at least on the remaining path length using the drive assembly and wherein the velocity is proportional to the remaining path length.
However, Atarot et al teach in the same medical field of endeavor, drive an elongated medical device at a velocity determined based at least on a remaining path length using a drive assembly and wherein the velocity is proportional to the remaining path length (the velocity of the endoscope’s movement will be adjusted as a function of the distance of the endoscope’s tip from the organ/tissue – [0570]).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to modify the velocity and advancement of the elongated medical device of Cohen et al as modified by Soper et al with the adjustment of the velocity as it would optimize the elongated medical device movements as it arrives closer to the target while decreasing the likelihood that it will contact incorrect tissue (Atarot et al – [0569]).
Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cohen et al (2015/0282890) in view of Soper et al (2013/0158346) and further in view of Atarot et al (2017/0202624) as applied to claim 1 above, and further in view of Dutta et al (2018/0336676).
Regarding claims 2 and 3, Cohen et al as modified by Soper et al and Atarot et al disclose the invention as claimed and discussed above, but fail to explicitly disclose wherein the controller is further programmed to determine whether at least one child vessel is connected to the path and wherein the controller is further programmed to display the mask and the child vessel mask on an image associated with the mask on a display.
However, Dutta et al teach in the same medical field of endeavor, wherein a controller is programmed to determine whether at least one child vessel (kissing vessel – [0032]) is connected to a path (a refined mask by eliminating vessels that are indirectly connected to an aneurysm or parent vessel – claim 1) and wherein the controller is further programmed to display the mask (parent mask) and a child vessel mask on an image associated with the mask on a display (generating a parent vessel mask based on the refined mask and generating a final mask for image segmentation – claim 1).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to modify the generating a mask of the path and masking of a given feature of Cohen et al as modified by Soper et al and Atarot et al with determining whether a child vessel is connected to a path and displaying the mask and the child vessel mask on an image associated with the mask of Dutta et al as it would provide isolation of the feature of interest in an image (abstract – Dutta).
Allowable Subject Matter
Claims 5-22 are allowable over the prior art; however, the claims are subject to an outstanding Double Patenting Rejection. Claims 7, 19 and 20 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims as well as overcoming the Double Patenting Rejection.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROCHELLE DEANNA TURCHEN whose telephone number is (571)270-7104. The examiner can normally be reached Mon - Fri 6:30-2:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher Koharski can be reached at (571)272-7230. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ROCHELLE D TURCHEN/ Primary Examiner, Art Unit 3797